Medicine & Life Sciences
tandutinib
100%
Sunitinib
93%
Acute Myeloid Leukemia
84%
Phosphotransferases
83%
fms-Like Tyrosine Kinase 3
81%
Protein-Tyrosine Kinases
66%
Daunorubicin
61%
PD 180970
53%
Receptor Protein-Tyrosine Kinases
44%
Semaxinib
40%
Mutation
36%
Quinoxalines
35%
Gallbladder Neoplasms
31%
Systemic Mastocytosis
26%
Gastrointestinal Stromal Tumors
21%
tyrphostin AGL-2043
20%
Catalytic Domain
16%
Neoplasms
14%
Drug Therapy
14%
gemcitabine
13%
Apoptosis
12%
Cell Line
12%
X Ray Crystallography
11%
In Vitro Techniques
10%
Phosphorylation
8%
Oxindoles
8%
Induction Chemotherapy
8%
Cell Proliferation
8%
Solubility
8%
Cardiac Myocytes
7%
Clinical Trials, Phase I
7%
STAT3 Transcription Factor
7%
Biological Availability
7%
Growth
7%
Smooth Muscle Myocytes
7%
Imatinib Mesylate
6%
Proteins
6%
Biliary Tract
6%
Inhibitory Concentration 50
6%
Therapeutics
6%
Swine
6%
Heterografts
6%
Adjuvant Chemotherapy
6%
Gain of Function Mutation
5%
Fluorouracil
5%
Laparoscopy
5%
Granulocyte Precursor Cells
5%
Bone Marrow
5%
Chemical Compounds
Phosphotransferase Inhibitor
69%
Tyrosine
68%
Mutation
47%
Oncogenic
45%
Cytarabine
39%
Tyrosine Kinase Inhibitor
36%
Daunorubicin
34%
Quinoxaline
27%
Cellular Property
13%
Protein
10%
Antileukemic Agent
9%
Dose
9%
Imatinib
9%
Bioavailability
7%
Antineoplastic Agent
7%
X-Ray Crystallography
6%
Indolinone
6%
Drug
6%
Refractory
6%
Compound Isomer
5%
Solubility
5%